These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 27514287)

  • 1. Myeloid cells - targets of medication in multiple sclerosis.
    Mishra MK; Yong VW
    Nat Rev Neurol; 2016 Sep; 12(9):539-51. PubMed ID: 27514287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells as therapeutic targets in neuroinflammation.
    Luessi F; Zipp F; Witsch E
    Cell Mol Life Sci; 2016 Jul; 73(13):2425-50. PubMed ID: 26970979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective roles for myeloid cells in neuroinflammation.
    Owens T; Benmamar-Badel A; Wlodarczyk A; Marczynska J; Mørch MT; Dubik M; Arengoth DS; Asgari N; Webster G; Khorooshi R
    Scand J Immunol; 2020 Nov; 92(5):e12963. PubMed ID: 32851668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do not judge a cell by its cover--diversity of CNS resident, adjoining and infiltrating myeloid cells in inflammation.
    Brendecke SM; Prinz M
    Semin Immunopathol; 2015 Nov; 37(6):591-605. PubMed ID: 26251238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
    Agahozo MC; Peferoen L; Baker D; Amor S
    Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation.
    Hwang D; Seyedsadr MS; Ishikawa LLW; Boehm A; Sahin Z; Casella G; Jang S; Gonzalez MV; Garifallou JP; Hakonarson H; Zhang W; Xiao D; Rostami A; Zhang GX; Ciric B
    Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2111804119. PubMed ID: 35353625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis.
    White M; Webster G; O'Sullivan D; Stone S; La Flamme AC
    PLoS One; 2014; 9(1):e87712. PubMed ID: 24498172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRP1 expression in microglia is protective during CNS autoimmunity.
    Chuang TY; Guo Y; Seki SM; Rosen AM; Johanson DM; Mandell JW; Lucchinetti CF; Gaultier A
    Acta Neuropathol Commun; 2016 Jul; 4(1):68. PubMed ID: 27400748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of dietary salt intake for multiple sclerosis pathogenesis.
    Hucke S; Wiendl H; Klotz L
    Mult Scler; 2016 Feb; 22(2):133-9. PubMed ID: 26447064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):21-31. PubMed ID: 27758698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 13. Effector and regulatory B cells in Multiple Sclerosis.
    Staun-Ram E; Miller A
    Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.
    Melnikov M; Rogovskii V; Boykо A; Pashenkov M
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):37-47. PubMed ID: 31011885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-mediated CNS damage.
    Kierdorf K; Wang Y; Neumann H
    Results Probl Cell Differ; 2010; 51():173-96. PubMed ID: 19130024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease.
    Codarri L; Greter M; Becher B
    Trends Immunol; 2013 Mar; 34(3):114-9. PubMed ID: 23116549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prospects of minocycline in multiple sclerosis.
    Chen X; Ma X; Jiang Y; Pi R; Liu Y; Ma L
    J Neuroimmunol; 2011 Jun; 235(1-2):1-8. PubMed ID: 21565409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm.
    Batoulis H; Addicks K; Kuerten S
    Ann Anat; 2010 Aug; 192(4):179-93. PubMed ID: 20692821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
    Kasper LH; Shoemaker J
    Neurology; 2010 Jan; 74 Suppl 1():S2-8. PubMed ID: 20038759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.